Who are KamRAB - HRIG's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): HyperRAB, Rabies immune globulin (human), Rabivax-S, Cell-culture rabies vaccine, Human rabies immunoglobulins, HDCV Comparator.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/kamrab-hrig.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

KamRAB - HRIG — Competitive Intelligence Brief

KamRAB - HRIG (KamRAB - HRIG) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Human rabies immunoglobulin (HRIG). Area: Infectious Disease / Immunology.

phase 3 Human rabies immunoglobulin (HRIG) Rabies virus glycoprotein Infectious Disease / Immunology Small molecule Live · refreshed every 30 min

Target snapshot

KamRAB - HRIG (KamRAB - HRIG) — Kamada, Ltd.. KamRAB is a human rabies immunoglobulin (HRIG) that provides passive immunity by supplying antibodies against rabies virus.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
KamRAB - HRIG TARGET	KamRAB - HRIG	Kamada, Ltd.	phase 3	Human rabies immunoglobulin (HRIG)	Rabies virus glycoprotein
HyperRAB	HyperRAB	Bio Products Laboratory	marketed	Rabies immunoglobulin (human)	Rabies virus glycoprotein
Rabies immune globulin (human)	Rabies immune globulin (human)	Sanofi Pasteur, a Sanofi Company	marketed	Passive immunizing agent; immunoglobulin	Rabies virus glycoprotein
Rabivax-S	Rabivax-S	University of Oxford	marketed	Rabies vaccine	Rabies virus glycoprotein
Cell-culture rabies vaccine	Cell-culture rabies vaccine	GlaxoSmithKline	phase 3	Inactivated viral vaccine	Rabies virus glycoprotein
Human rabies immunoglobulins	Human rabies immunoglobulins	Sanofi Pasteur, a Sanofi Company	phase 3	Immunoglobulin (passive immunization)	Rabies virus glycoprotein
HDCV Comparator	HDCV Comparator	Wilbur Chen, MD, MS	phase 3	Inactivated viral vaccine	Rabies virus glycoprotein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Human rabies immunoglobulin (HRIG) class)

Kamada, Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). KamRAB - HRIG — Competitive Intelligence Brief. https://druglandscape.com/ci/kamrab-hrig. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab